The mean number of infections was 2.4 /pt with no difference between the groups in incidence, type of pathogens (bacterial, fungal, viral) or severity. There was a significant difference in VOD in all IVIG groups, with no cases in the placebo group (p =.025). VOD was fatal in 2 pts of Group 3 and 5 pts of Group 4.
In the preliminary analysis of this multicenter study, there was no benefit of IVIG, at any dose, over placebo, in prevention of overall infection, IP, or GVHD, or in day 180 survival. VOD occurred in no placebo pt, but in 10-17% of IVIG pts, with increased severity and mortality in those treated at 250 and 500 mg/kg/w.
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Severe infections after reduced-intensity allogeneic PBSCT: a comparative study with conventional myeloablative PBSCT R. Martino, M.D. Caballero, C. Canals, C. Solano, M. Rovira, J. Bargay, J. Sierra, J.F. San Miguel, R. De la Camara (Barcelona, Salamanca, Valencia, Palma de Mallorca, Madrid, for the IDWP of GETH, E)
We have compared the occurrence of severe infections following 60 reduced-intensity allogeneic PBSCT and 123 myeloablative unmanipulated PBSCT (MINI and CONV groups, respectively) from HLA-identical siblings. Baseline patient characteristics diferred in several points, including age (median 54 vs 38, PϽ0.0001) and non-early disease phase (79% vs 56%, respectively, P=0.04). The probability of infection-related mortality was 12% in the MINI group and 19% in the CONV group (P=0.5). The probability of developing CMV infection was 28% in the MINI group and 39% in the CONV group (P=0.2), although the proportion of CMV seropositive donor/recipient pairs was higher in the MINI group (99% vs 88%, respectively, P=0.04). The probabilities of CMV disease were 3% and 10%, respectively (P=0.1). Disseminated varicella-zoster virus infection occurred in 10% of the MINI group and and 12% in the CONV group. Invasive fungal infections (12% vs 14%) and pneumonias of unknown origin (16% vs 24%) did not differ between groups. Early and late bacterial infections were also similar between groups. Our results suggest that reduced-intensity allogeneic PBSCT may decrease the risk of suffering severe infectious complications, since all infections showed a trend for being lower in the MINI group while baseline patient characteristics in these patients were of poorer prognosis. In order to study the influence of CD34+ cell dose on BMT outcomes, we retrospectively analyzed 212 consecutive patients transplanted from 01/94 to 08/ 99 with an unmanipulated BMT from an HLA-identical sibling donor. Median follow up was 3.2
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years. Median age was 30.8 (range 3.3-56) years, 176 patients had malignancies (ALL/AML 49.4%, CML 31.3%, others 19.3%), of whom 27 (13%) were transplanted in an advanced stage of disease. An irradiation-based conditioning was used in 86 (40.6%) patients. As acute graft-versus-host disease (GVHD) prophylaxis, all patients received cyclosporin A (CsA), associated with methotrexate in 82%. Median number of nucleated cells (NC) and CD34+ cells infused were respectively 2.4x108/kg (range: 0.28-5.97) and 3.7x106/kg (range: 0.07-18.7). Estimate 5-year survival, 180-day transplant-related mortality (TRM), 60-days neutrophil engraftment and aGVHD were 56%, 25%, 99%, and 49% respectively. In multivariate analyses, no correlation was observed between CD34+ cell dose and neutrophil engraftment, acute and chronic GVHD, and bacterial and viral infections. However, the CD34+ cell dose higher than 3x106/kg significantly influenced survival (Relative risk 0. The HLA-identical sibling donors of 84 adult allogeneic BMT recipients were randomized to receive or not to receive pneumococcal polysaccharide (Pnc PS) vaccine and Haemophilus influenzae type b (Hib) oligosaccharide mutant diphtheria toxin (CRM197) conjugate vaccine 2-12 weeks before bone marrow harvest. Forty-one BMT recipients received the graft from a vaccinated donor, 43 recipients from an unvaccinated donor. All recipients were vaccinated with the Pnc PS vaccine at 12 months and with the Hib conjugate vaccine at 3, 6, and 12 months after transplantation. IgG antibody concentrations to Pnc serotypes 6B, 14, 19F, 23F, and Hib were determined by an EIA method in sera drawn from the patients prior to BMT, just before and one month after each vaccination. IgG antibody concentrations to all investigated Pnc serotypes decreased after BMT, and the geometric mean concentrations (GMC) were similar in the vaccinated donor group and unvaccinated donor group patients at 12 months after BMT. The GMCs of IgG Pnc PS antibodies increased approximately two-fold after vaccination with the Pnc PS vaccine, and the post-vaccination GMCs of anti-Pnc type 6B, 14, 19F, and 23F were 0.59, 1.67, 1.54, and 0.69 ug/ml in the patients of the vaccinated donor group and 0.42, 1.44, 0.99, and 0.56 ug/ml in the patients of the unvaccinated donor group, similar in both groups. The Hib conjugate vaccine induced slight IgG antibody responses already at 3 months after BMT, and vaccination at 6 months after BMT elicited clear responses: The GMC of anti-Hib increased from 2.15 to 14.68 ug/ml in the vaccinated donor group patients, and from 1.53 to 4.30 ug/ml in the unvaccinated donor group patients. After the 12-month vaccine dose the GMC of IgG Hib antibodies increased from 5.52 to 43.63 ug/ml in the vaccinated donor group patients and from 2.24 to 13.41 ug/ml in the unvaccinated donor group patients. The GMC of IgG Hib antibodies was significantly higher after the 6-month vaccine dose (p=0.04) and tended to be higher after the 12-month vaccine dose (p=0.10) in the vaccinated donor group patients than in the unvaccinated donor group patients.
In conclusion, immunization of the bone marrow donors with the Hib conjugate vaccine before marrow harvest resulted in higher IgG Hib antibody concentrations after the second vaccine dose at six months and a tendencey for higher IgG anti-Hib concentrations after the third vaccine dose at 12 months after BMT. Vaccination of the donors with the plain Pnc PS vaccine had no influence on the immunogenicity of the vaccine in the recipients. In a prospective study we evaluated the feasibility and efficacy of leucocyte transfusions (LT) in patients with malignancies or haematological disorders who were suffering from severe bacterial (n = 30 pts) or fungal infection (n = 17) during therapy related bone marrow aplasia. Fourty seven patients with severe neutropenia and clinical signs of life-threatening sepsis not responding to adequate treatment, received LT from G-CSF-stimulated family donors or from prednisolone-primed volunteers. A total of 528 LT were administered. All leucocyte concentrates were irradiated with 30 Gy and infused as soon as possible after harvesting. The median number of LT per patient was 7 (range, 3-65), the median duration of LT treatment was 8 days (range, 2 -35). The absolute white blood cell count, absolute neutrophile count and lymphocyte count of the concentrates from rG-CSFstimulated donors were significantly higher than those from prednisolone-primed volunteers (p = 0.0001). Despite the critical condition of the patients, LT were generally tolerated well. 168 (32%) LT were associated with adverse reactions. The most common side effects were fever, chills and transient dyspnea. Only 2% of the observed side effects exceeded the WHO II standards. The transfusion of leucocytes collected by continuous flow leucapheresis from both G-CSF and prednisolone stimulated donors resulted in a measurable increment of the peripheral leucocyte and ANC counts in our patients. On day 28 after the first LT, 76% of the patients were alive with clearance of the infection. In conclusion, leucocyte transfusions are feasible in critically ill patients with severe neutropenia and bacterial or fungal infections. The side effects of stimulation and apheresis are tolerable for the donors. The beneficial effect of LT for the control of severe infections in patients irresponsive to adequate conventional treatment are currently investigated in a randomised multicentre trial.
OS216
Clinical impact of a prospective, sequential diagnostic approach for the study of pulmonary infiltrates in Hematopoietic Cell Transplantation (HCT).
M. Rovira, A. Rañ ó , E. Carreras, C. Dané s, J. Gonzá lez, F. Ferná ndez-Avilé s, A. Torres, E. Montserrat (Barcelona, E)
The development of pulmonary infiltrates (PI) in immunocompromised patients is a frequent life-threatening complication requiring early diagnosis and treatment. Over a 30-month period, we prospectively evaluated all consecutive HCT patients with PI with the same diagnostic approach that included non-invasive and bronchoscopic techniques. Non-invasive methods were: serologic tests; blood antigen detection; blood, sputum, nasopharyngeal wash (NPW) and tracheobronchial aspirates (TBAS) cultures. Bronchoscopic techniques included protected specimen brush (PSB) and bronchoalveolar lavage (BAL). We analyzed the impact of this procedure on diagnosis and outcome. Overall, 61 patients with PI were evaluated: 52 had received an allogeneic HCT and 9 an autologous HCT. An etiological diagnosis was obtained in 47 (77 %) patients. The etiology was infectious in 33 (70 %) and non-infectious in 14 (30%) . Fourteen episodes (23%) remained undiagnosed. The main infectious etiologies were viral (36%), fungal (24%), bacterial (21%), and polymicrobial (15%).The most frequent pathogen were Aspergillus fumigatus (n= 6), cytomegalovirus (n=6) and Candida spp (n=3).The most common non-infectious etiologies were pulmonary edema (23%) and diffuse alveolar hemorrhage (38%). Non-invasive techniques led to the diagnosis in 38% of the episodes. The diagnostic yield of blood culture was 16%, of sputum cultures 24%, of NPW 15%, and of TBAS 29%. Bronchoscopic techniques were diagnostic in 53% of the episodes in which they were employed (BAL 44% and PSB 16%). Antibiotic treatment was changed according to the results obtained with the different techniques in 48% episodes. The overall mortality was 52.5% , this being higher in those patients with an infectious etiology (64%) as compared to those with a non-infectious etiology (28%) (p:0.05) and also in those patients requiring mechanical ventilation (97%) in comparison to those not requiring it (10%) (p Ͻ 0.0001). In the univariate analysis the following variables were related to a poor prognosis: APACHE II score Ͼ 20, PaO2/FiO2 Ͻ 250, bilateral radiographic involvement and mechanical ventilation. This last factor was the only one that remained significant in multivariate analysis. Although the diagnostic yield of PI has improved with this approach, allowing an etiology-adjusted treatment, the mortality in this population is still too high. TBAS and BAL showed the highest diagnostic yield and impact on therapeutic decisions.
